Allogene Therapeutics Inc ALLO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Allogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Trading Information
- Previous Close Price
- $1.09
- Day Range
- $0.98–1.13
- 52-Week Range
- $0.98–4.46
- Bid/Ask
- $1.04 / $1.08
- Shares Outstanding
- 346.47M
- Market Cap
- $359.31M
- Volume/Avg
- 13M / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 64.02
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 152
- Website
- https://www.allogene.com
Valuation
Metric | ALLO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.92 |
Price/Sales | 64.02 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ALLO |
|---|---|
Quick Ratio | 7.61 |
Current Ratio | 7.79 |
Interest Coverage | −142.24 |
Quick Ratio
ALLO
Profitability
Metric | ALLO |
|---|---|
Return on Assets (Normalized) | −29.96% |
Return on Equity (Normalized) | −40.40% |
Return on Invested Capital (Normalized) | −36.90% |
Return on Assets
ALLO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|C@^<?dx | LOCK|^r&^q | $139B | |||
| Moderna Inc MRNA | LOCK|zHdG@zR | LOCK|Z?# | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|>Xmjrx | LOCK|R@@! | $94B | |||
| argenx SE ADR ARGX | LOCK|V?@%j?D | LOCK|>w | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$kgP!B$ | LOCK|tm | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|%!gKx<B& | LOCK|Hd$$ | $30B | |||
| Incyte Corp INCY | LOCK|y@<!C? | LOCK|MR< | $24B | |||
| BioNTech SE ADR BNTX | LOCK|!h^#!> | LOCK|>> | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Z?LBP#n | LOCK|@%^@ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|kRn@J? | LOCK|pZ | $15B |
United States